Patents by Inventor Alain Thierry
Alain Thierry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124940Abstract: Methods for screening a subject for a cancer are provided. In particular, the methods include i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.Type: ApplicationFiled: October 5, 2023Publication date: April 18, 2024Inventors: Alain THIERRY, Safia EL MESSAOUDI
-
Publication number: 20230399702Abstract: The present invention relates to the diagnostic of cancerous subject. Indeed, the inventors observed by using a Q-PCR based methods and sequencing methods that quantification of specific single stranded DNA fragments obtained from cell free nucleic acids (cfDNA) may discriminate cfDNA from healthy and cancer derived subjects. Single stranded DNA fragments obtained from CfDNA or specific range of single stranded DNA fragments are rather lower or higher when derived from healthy subject than from cancer subject. More, specific ratios for different size or range of single stranded DNA fragments varies between cancer subjects and healthy individuals. These values are sufficiently and significantly different to be used as values to determine whether a human subject may have cancer or not as a screening test.Type: ApplicationFiled: July 20, 2023Publication date: December 14, 2023Inventors: Alain THIERRY, Cynthia SANCHEZ
-
Patent number: 11821044Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.Type: GrantFiled: June 23, 2020Date of Patent: November 21, 2023Assignees: INSTITUT NATIONAL DE LA SANTÈ ET DE LA RECHERCHE MÈDICALE, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIERInventors: Alain Thierry, Safia El Messaoudi
-
Patent number: 11814686Abstract: The present invention relates to the diagnostic of cancerous subject. Indeed, the inventors observed by using a Q-PCR based methods and sequencing methods that quantification of specific single stranded DNA fragments obtained from cell free nucleic acids (cfDNA) may discriminate cfDNA from healthy and cancer derived subjects. Single stranded DNA fragments obtained from CfDNA or specific range of single stranded DNA fragments are rather lower or higher when derived from healthy subject than from cancer subject. More, specific ratios for different size or range of single stranded DNA fragments varies between cancer subjects and healthy individuals. These values are sufficiently and significantly different to be used as values to determine whether a human subject may have cancer or not as a screening test.Type: GrantFiled: December 6, 2018Date of Patent: November 14, 2023Assignees: INSTITUT NATIONAL DE LA SANTÉDE LA RECHERCHE MÉDICALE, UNIVERSITÉ de MONTPELLIER, INSTITUT RéGIONAL DU CANCER DE MONTPELLIERInventors: Alain Thierry, Cynthia Sanchez
-
Patent number: 11674183Abstract: The present invention is directed to an in vitro method of detecting cell free nucleic acids, preferably cell free DNA (cfDNA) in a body fluid sample from an individual or a patient, wherein the method comprises the step of accurately and sensitively determining the concentration of cell free nucleic acid in the sample and/or determining the concentration or amount of said cell free nucleic acid of a size range and/or the index of integrity or size fraction ratio (SFR) of said cell free nucleic acid and/or the determination of the presence of genetic polymorphisms (such as known Single Nucleotide Polymorphisms (SNPs) or mutations). The invention encompasses also a method to discriminate body fluid individuals where cfDNA are highly released by comparing the size profile obtained for at least one of three size ranges of cfDNA.Type: GrantFiled: August 5, 2019Date of Patent: June 13, 2023Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Alain Thierry, Franck Molina
-
Publication number: 20220290244Abstract: The present invention relates to the field of cancer diagnostic. Here, the inventors observed by using conventional DSP sequencing method that size profile of double stranded DNA fragments obtained from cell free nucleic acids (cfDNA) may discriminate cfDNA from healthy and cancer derived subjects as previously observed (Jiang et al). Contrary to the prior art, the inventors determined specific double stranded DNA fragments or range of fragments and showed that these the number of these specific fragments are different between healthy and cancerous subjects. The number of double stranded DNA fragments as quantified from CfDNA are rather lower or higher when derived from healthy subject than from cancer subject. The invention provides description of calculation or biomarker from the identification of specific DNA fragments, specific ratios for different size or range of double stranded DNA fragment towards discriminating cancer to healthy plasma.Type: ApplicationFiled: July 31, 2020Publication date: September 15, 2022Inventor: Alain THIERRY
-
Publication number: 20220106643Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non invasive methods and kits for determining the quality of an embryo by determining the level of the cell free nucleic acids and/or determining the presence and/or expression level of at least one specific nucleic acid sequence in the nucleic acid extraction.Type: ApplicationFiled: September 13, 2021Publication date: April 7, 2022Inventors: Samir HAMAMAH, Safia EL MESSAOUDI, Alain THIERRY, Said ASSOU
-
Publication number: 20220073993Abstract: The present invention relates to methods, materials and kits for detecting mutations in the EGFR gene. The invention also relates to methods for detecting or diagnosing cancer in a subject, as well as for determining the clinical stage, and clinical progression of a cancer.Type: ApplicationFiled: June 20, 2019Publication date: March 10, 2022Inventors: ALAIN THIERRY, BARBARA OTTOLINI
-
Patent number: 11149314Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non invasive methods and kits for determining the quality of an embryo by determining the level of the cell free nucleic acids and/or determining the presence and/or expression level of at least one specific nucleic acid sequence in the nucleic acid extraction.Type: GrantFiled: September 19, 2018Date of Patent: October 19, 2021Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, Institut Régional du Cancer de MontpellierInventors: Samir Hamamah, Safia El Messaoudi, Alain Thierry, Said Assou
-
Publication number: 20210172019Abstract: The present invention relates to the diagnostic of cancerous subject. Indeed, the inventors observed by using a Q-PCR based methods and sequencing methods that quantification of specific single stranded DNA fragments obtained from cell free nucleic acids (cfDNA) may discriminate cfDNA from healthy and cancer derived subjects. Single stranded DNA fragments obtained from CfDNA or specific range of single stranded DNA fragments are rather lower or higher when derived from healthy subject than from cancer subject. More, specific ratios for different size or range of single stranded DNA fragments varies between cancer subjects and healthy individuals. These values are sufficiently and significantly different to be used as values to determine whether a human subject may have cancer or not as a screening test.Type: ApplicationFiled: December 6, 2018Publication date: June 10, 2021Inventors: Alain THIERRY, Cynthia SANCHEZ
-
Publication number: 20200399707Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.Type: ApplicationFiled: June 23, 2020Publication date: December 24, 2020Inventors: Alain THIERRY, Safia EL MESSAOUDI
-
Patent number: 10704104Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.Type: GrantFiled: October 20, 2015Date of Patent: July 7, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIERInventors: Alain Thierry, Safia El Messaoudi
-
Publication number: 20190352725Abstract: The present invention is directed to an in vitro method of detecting cell free nucleic acids, preferably cell free DNA (cfDNA) in a body fluid sample from an individual or a patient, wherein the method comprises the step of accurately and sensitively determining the concentration of cell free nucleic acid in the sample and/or determining the concentration or amount of said cell free nucleic acid of a size range and/or the index of integrity or size fraction ratio (SFR) of said cell free nucleic acid and/or the determination of the presence of genetic polymorphisms (such as known Single Nucleotide Polymorphisms (SNPs) or mutations). The invention encompasses also a method to discriminate body fluid individuals where cfDNA are highly released by comparing the size profile obtained for at least one of three size ranges of cfDNA.Type: ApplicationFiled: August 5, 2019Publication date: November 21, 2019Inventors: Alain Thierry, Franck Molina
-
Publication number: 20190002985Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non invasive methods and kits for determining the quality of an embryo by determining the level of the cell free nucleic acids and/or determining the presence and/or expression level of at least one specific nucleic acid sequence in the nucleic acid extraction.Type: ApplicationFiled: September 19, 2018Publication date: January 3, 2019Inventors: Samir HAMAMAH, Safia EL MESSAOUDI, Alain THIERRY, Said ASSOU
-
Publication number: 20180046716Abstract: In one example, documents that are examined by a search process may be scored in a manner that is specific to a domain. A domain may be a substantive area, such as medicine, sports, etc. Different scoring approaches that take aspects of the domain into account may be applied to the documents, thereby producing different scores than might have been produced by a simple comparison of the terms in the query with the terms in the documents. These domain-based approaches may take a query into account in scoring the documents, or may be query-independent. Each approach may be implemented by a scorer. The combined output of the scorers may be used to generate a score for each document. Documents then may be ranked based on the scores, and search results may be provided.Type: ApplicationFiled: October 24, 2017Publication date: February 15, 2018Inventors: Alain Thierry RAPPAPORT, Daniel ADAMSON
-
Patent number: 9836538Abstract: In one example, documents that are examined by a search process may be scored in a manner that is specific to a domain. A domain may be a substantive area, such as medicine, sports, etc. Different scoring approaches that take aspects of the domain into account may be applied to the documents, thereby producing different scores than might have been produced by a simple comparison of the terms in the query with the terms in the documents. These domain-based approaches may take a query into account in scoring the documents, or may be query-independent. Each approach may be implemented by a scorer. The combined output of the scorers may be used to generate a score for each document. Documents then may be ranked based on the scores, and search results may be provided.Type: GrantFiled: March 3, 2009Date of Patent: December 5, 2017Assignee: MICROSOFT TECHNOLOGY LICENSING, LLCInventors: Alain Thierry Rappaport, Daniel Adamson
-
Publication number: 20170240975Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.Type: ApplicationFiled: October 20, 2015Publication date: August 24, 2017Inventors: Alain THIERRY, Safia EL MESSAOUDI
-
Publication number: 20170183742Abstract: The present invention relates to methods for predicting the survival time of patients suffering from cancer. Said methods are based on the quantification and analysis of the cell free nucleic acids that are present in a sample from the patient and typically include the determination of the level of the mutant nucleic acid which contains a mutation of interest, the calculation of the mutation load for said mutation of interest, the calculation of the DNA integrity index or a combination thereof.Type: ApplicationFiled: May 27, 2015Publication date: June 29, 2017Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIERInventors: Alain THIERRY, Safia MESSAOUDI, Florent MOULIERE
-
Publication number: 20170166982Abstract: The present invention is directed to an in vitro method of detecting cell free nucleic acids, preferably cell free DNA (cfDNA) in a body fluid sample from an individual or a patient, wherein the method comprises the step of accurately and sensitively determining the concentration of cell free nucleic acid in the sample and/or determining the concentration or amount of said cell free nucleic acid of a size range and/or the index of integrity or size fraction ratio (SFR) of said cell free nucleic acid and/or the determination of the presence of genetic polymorphisms (such as known Single Nucleotide Polymorphisms (SNPs) or mutations). The invention encompasses also a method to discriminate body fluid individuals where cfDNA are highly released by comparing the size profile obtained for at least one of three size ranges of cfDNA.Type: ApplicationFiled: February 24, 2017Publication date: June 15, 2017Inventors: ALAIN THIERRY, FRANCK MOLINA
-
Patent number: 9580755Abstract: The present invention is directed to an in vitro method of detecting cell free nucleic acids, preferably cell free DNA (cfDNA) in a body fluid sample from an individual or a patient, wherein the method comprises the step of accurately and sensitively determining the concentration of cell free nucleic acid in the sample and/or determining the concentration or amount of said cell free nucleic acid of a size range and/or the index of integrity or size fraction ratio (SFR) of said cell free nucleic acid and/or the determination of the presence of genetic polymorphisms (such as known Single Nucleotide Polymorphisms (SNPs) or mutations). The invention encompasses also a method to discriminate body fluid individuals where cfDNA are highly released by comparing the size profile obtained for at least one of three size ranges of cfDNA.Type: GrantFiled: September 5, 2011Date of Patent: February 28, 2017Assignee: Centre National de la Recherche Scientifique (CNRS)Inventors: Alain Thierry, Franck Molina